Iradimed Corporation (NASDAQ:IRMD) Sees Significant Growth in Short Interest

Iradimed Corporation (NASDAQ:IRMDGet Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 112,900 shares, a growth of 11.0% from the February 29th total of 101,700 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 54,200 shares, the short-interest ratio is presently 2.1 days.

Iradimed Stock Down 0.4 %

NASDAQ:IRMD opened at $42.71 on Wednesday. Iradimed has a 12-month low of $36.12 and a 12-month high of $51.04. The firm has a market capitalization of $540.71 million, a PE ratio of 31.40 and a beta of 0.82. The firm has a 50-day moving average price of $43.81 and a 200 day moving average price of $43.26.

Iradimed (NASDAQ:IRMDGet Free Report) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.01). Iradimed had a return on equity of 24.62% and a net margin of 26.22%. The business had revenue of $17.45 million during the quarter.

Institutional Trading of Iradimed

Hedge funds have recently modified their holdings of the company. Copeland Capital Management LLC acquired a new stake in shares of Iradimed during the third quarter worth approximately $30,000. Tower Research Capital LLC TRC increased its holdings in shares of Iradimed by 51.4% during the third quarter. Tower Research Capital LLC TRC now owns 1,131 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 384 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Iradimed during the third quarter worth approximately $36,000. Dark Forest Capital Management LP acquired a new stake in shares of Iradimed during the first quarter worth approximately $59,000. Finally, AJOVista LLC acquired a new stake in shares of Iradimed during the fourth quarter worth approximately $66,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Iradimed Company Profile

(Get Free Report)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.

See Also

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.